Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

Inclusion Criteria: * Advanced lymphoid leukemia (primary refractory ALL; Relapsed ALL; CML in lymphoid accelerated phase or blast crisis; relapsed or refractory Burkitt's lymphoma; relapsed or refractory T-cell adult leukemia/lymphoma; relapsed or refractory lymphoblastic lymphoma * \>= 18 and \<= 65 years of age ECOG performance status 0, 1 Life expectancy \>= 4 weeks Able to consume oral medication Required initial laboratory values: Creatinine \<= 2.0mg/dL, total or direct bilirubin \<= 1.5 mg/dL, SGPT(ALT) \<=ULN, glucose \< 200 mg/dL, negative pregnancy test for women with child bearing potential Exclusion Criteria: * Subjects must not be receiving any chemotherapy agents (except Hydroxyurea) * Subjects must not have received high-dose Ara-C within 6 months of relapse * Subjects must not be receiving growth factors, except for erythropoietin * No currently active second malignancy other than non-melanoma skin cancers * No subjects with uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, MI within the last 6 months or serious uncontrolled cardiac arrhythmia * Subjects taking Carbamazepine, Rifabutin, Rifampin, Rifapentine, St. John's wort, Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Telithromycin, Verapamil, Tacrolimus * Known HIV positivity or AIDS-related illness * Evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with Ara-C administration * Pregnant or lactating * Uncontrolled infection * Taking fluconazole, voriconazole, itraconazole and ketoconazole currently or within one week of study entry